Why AbbVie Stock Jumped Today
Source: Motley Fool
2026-06-22 23:18:12 ET
Shares of AbbVie (NYSE: ABBV) climbed on Monday after the pharmaceutical giant struck a deal to acquire clinical-stage biotech Apogee Therapeutics (NASDAQ: APGE) for $10.9 billion.
Image source: The Motley Fool.
Under the terms of the deal, AbbVie would purchase Apogee for $135.11 per share in cash. That's a 49% premium over the stock's closing price on Thursday, the last trading day before the deal's announcement.
Apogee Therapeutics Inc.
NASDAQ: APGE
APGE Trading
0.13% G/L:
$133.75 Last:
388,018 Volume:
$133.55 Open:
APGE Latest News
July 11, 2026 08:35:00 pm
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
$4,474,975,000
36,961,244
2.65%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
